Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 7, 2018, the Board of Directors approved "inducement" grants to 3 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 47,000 shares of common stock.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Pasadena. CA | Posted on December 18th, 2018

The strike price of options is set at an exercise price per share of $13.66, the last reported closing price of the Company's common stock on December 10, 2018, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of one new employee, anticipated to be within 60 days of the date of the approval. The grants are outside of the Company's stockholder-approved equity incentive plans. The options vest and become exercisable over a period of four years.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanomaterials enable dual-mode heating and cooling device: Device could cut HVAC energy use by nearly 20% in the US December 2nd, 2020

Having it Both Ways: A Combined Strategy in Catalyst Design for Suzuki Cross-Couplings December 2nd, 2020

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Jobs

SEMI Partners with GLOBALFOUNDRIES to Offer Apprenticeship Program Aimed at Building the Electronics Talent Pipeline August 11th, 2020

March 17th, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 29th, 2019

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

Investments/IPO's/Splits

180 Degree Capital Corp. Reports +7.4% Growth and $2.90 Per Share NAV as of September 30, 2020, and Developments From Q4 2020 November 19th, 2020

Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results November 3rd, 2020

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 29th, 2020

180 Degree Capital Corp. Invests Additional Capital in TheMaven, Inc. and Provides QTD Public Portfolio Update (+22.1% / +$0.32 Per Share) September 10th, 2020

Nanomedicine

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

Announcements

Nanomaterials enable dual-mode heating and cooling device: Device could cut HVAC energy use by nearly 20% in the US December 2nd, 2020

Having it Both Ways: A Combined Strategy in Catalyst Design for Suzuki Cross-Couplings December 2nd, 2020

The National Space Society Remembers Ben Bova : NSS Mourns the Loss of a Visionary NSS Leader December 2nd, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

New platform generates hybrid light-matter excitations in highly charged graphene December 2nd, 2020

Graphenea awarded “Best Graphene Firm” prize October 20th, 2020

Revealing the reason behind jet formation at the tip of laser optical fiber October 16th, 2020

NSF renews Rice-based NEWT Center for water treatment: Partnership primed to introduce game-changing technologies to address global needs October 15th, 2020

Nanobiotechnology

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences December 2nd, 2020

An ionic forcefield for nanoparticles: Tunable coating allows hitch-hiking nanoparticles to slip past the immune system to their target November 27th, 2020

Quantum nanodiamonds may help detect disease earlier: The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by UCL research November 27th, 2020

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project